Approximately 80% of people with Alzheimer’s disease (AD) and related dementia rely on caregivers. In Europe, caregivers provide 0.9–5.0 hours per day of informal care for patients with dementia. Longitudinal studies have shown that their health-related quality of life (HRQoL) negatively trends over time. Using caregiver outcome assessments (CareOAs) in AD trials can capture the impact of treatment on caregiver burden, HRQoL, and time spent providing care. This abstract aims to conduct a landscape analysis of AD-specific CareOAs to evaluate the content of available assessments and inform future selections for clinical trials.
